Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, ...
How might this development influence analyst coverage, target price revisions, and overall investor sentiment toward Bioxytran?
Could the new precision diagnostics open up additional indications beyond stroke and Alzheimer’s, expanding the revenue opportunity?
What are the projected costs and margins for the diagnostic platform once it reaches commercial scale?
9 days ago